ivermectin in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
0.40 [0.13 ; 1.23 ] I-TECH (Lim), 2022, Krolewiecki, 2020, Shahbaznejad, 2020 3 0% 608 moderate not evaluable death or transfer to ICUdetailed results Soto-Becerra, 2020 1.58 [1.11; 2.25]
1.58 [1.11 ; 2.25 ] Soto-Becerra, 2020 1 0% 2,833 NA not evaluable deathsdetailed results Abd-Elsalam, 2021 0.74 [0.16; 3.42]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
Hashim A, 2020 0.48 [0.11; 1.99]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
Okumuş, 2020 0.58 [0.18; 1.91]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
0.43 [0.21 ; 0.87 ] Abd-Elsalam, 2021, Gonzalez (IVER), 2020, Hashim A, 2020, I-TECH (Lim), 2022, Kirti, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, Okumuş, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 6 0% 1,223 moderate not evaluable deaths (time to event analysis only)detailed results Soto-Becerra, 2020 1.39 [0.88; 2.21]
1.39 [0.88 ; 2.21 ] Soto-Becerra, 2020 1 0% 2,833 NA not evaluable clinical deteriorationdetailed results Hashim A, 2020 0.40 [0.10; 1.63]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
0.68 [0.29 ; 1.59 ] Hashim A, 2020, I-TECH (Lim), 2022, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 78% 993 moderate not evaluable clinical improvementdetailed results Camprubi, 2020 0.68 [0.12; 3.87]
Chachar, 2020 1.19 [0.38; 3.72]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Okumuş, 2020 1.51 [0.54; 4.24]
1.89 [1.06 ; 3.38 ] Camprubi, 2020, Chachar, 2020, NCT04523831 (Mahmud), 2020, Okumuş, 2020 1 0% 400 NA not evaluable clinical improvement (7-day)detailed results Camprubi, 2020 0.68 [0.12; 3.87]
Chachar, 2020 1.19 [0.38; 3.72]
Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
1.28 [0.61 ; 2.70 ] Camprubi, 2020, Chachar, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020 2 91% 475 moderate not evaluable clinical improvement (time to event analysis only)detailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable death or ventilationdetailed results Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
0.89 [0.30 ; 2.64 ] Gonzalez (IVER), 2020 1 0% 73 NA not evaluable hospital dischargedetailed results Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
Kirti, 2021 1.20 [0.73; 1.98]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
1.14 [0.71 ; 1.84 ] Gonzalez (IVER), 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 185 moderate not evaluable mechanical ventilationdetailed results Abd-Elsalam, 2021 1.00 [0.20; 5.11]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
0.52 [0.19 ; 1.42 ] Abd-Elsalam, 2021, I-TECH (Lim), 2022, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shahbaznejad, 2020 3 0% 675 moderate not evaluable viral clearance detailed results Camprubi, 2020 0.52 [0.10; 2.58]
Chaccour, 2020 0.92 [0.77; 1.09]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.92 [0.77 ; 1.09 ] Camprubi, 2020, Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 1 0% 24 NA not evaluable viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Bukhari, 2021 0.91 [0.02; 46.94]
3.54 [1.03 ; 12.13 ] Ahmed, 2020, Bukhari, 2021 2 0% 158 serious not evaluable viral clearance by day 7detailed results Bukhari, 2021 11.56 [3.53; 37.91]
Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.91 [0.77 ; 1.08 ] Bukhari, 2021, Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 136 low not evaluable ICU admissiondetailed results I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Kirti, 2021 0.90 [0.30; 2.70]
0.84 [0.39 ; 1.78 ] I-TECH (Lim), 2022, Kirti, 2021 2 0% 602 moderate not evaluable serious adverse eventsdetailed results Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
2.14 [0.21 ; 21.56 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 408 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
1.97 [0.55 ; 7.04 ] Chaccour, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 36% 432 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-12 14:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 684,886
- roots T: 290
